Drug Development Executive: Andreas Schütte, Member of the Management Board, Plastics & Devices Division, discusses his important role in Gerresheimer’s divisional restructuring process, and how he is convinced the new structure better reflects customer requirements.
In January, the FDA banned imports from a fourth Ranbaxy plant in India after an unscheduled inspection revealed a lab littered with flies, a leaking…
RESIDUAL IMPURITIES – Developing & Validating an Efficient Method to Determine Residuals of Hormone Products by LC-MS After Cleaning of Equipment
Geoff Carr, PhD, describes the benefits of LC-MS and presents an effective method using this technology to determine the potential residual amount of eight active ingredients used in oral contraceptive tablets after cleaning equipment used in their manufacture.
Thomas Otto believes a specialized CDMO can provide efficient solutions to the many challenges surrounding lyophilized substances. But it should be ascertained they have packaging, manufacturing, and lyophilization expertise.
Martin Magazzolo believes the cloud presents a strong alternative to costly internal solutions when managing content for R&D, allowing companies to shift their focus to innovation.
EXECUTIVE INTERVIEW – EMD Millipore: Enhancing the Bioavailability of Active Pharmaceutical Ingredients
Drug Development Executive: Steffen Denzinger, Head of Portfolio Development at EMD Millipore, talks about bioavailability challenges and how EMD Millipore’s formulation portfolio and expertise are helping the pharmaceutical industry achieve maximum efficacy with APIs.
EXECUTIVE INTERVIEW – Battelle: Innovation in Drug Delivery Through Integrated Science & Engineering
Drug Development Executive: Amy Heintz, PhD, Senior Research Scientist at Battelle, speaks about the company’s relationship with customers and the importance of integrating device design, formulation, and human factors in the development of safe and efficient drug delivery solutions.
MANAGEMENT INSIGHT – Six Reasons Why the Affordable Care Act May Be a Bad-Tasting Medicine That Could Heal Our Industry
Derek Hennecke says that whether you love the Affordable Care Act (ACA) or abhor it, the fact is, there are billions of dollars of government money in play and some industries are going to benefit tremendously.
Pierre Carlotti, Vice-President of Marketing and Communication for Aptar Pharma Prescription Division, talks about the market for auto-injectors and some relevant market trends, and explains how his company went about designing and developing a novel auto-injector.
BIOAVAILABILITY ENHANCEMENT – Navigating a Broad Spectrum of Solubilization Technologies: Part III of III
Marshall Crew, PhD, President & CEO, Agere Pharmaceuticals, Inc., concludes his multiple-part series discussing today’s most challenging issues in solubility.
EXCLUSIVE ONLINE CONTENT
Immatics N.V. recently announced the extension of its cell therapy manufacturing collaboration with The University of Texas Health Science Center at Houston (UTHealth)….
Catalent recently announced that it will expand its Argentinian site in Loma Hermosa, Buenos Aires. The expansion, which will add over….
Editas Medicine Enters Into Strategic Partnership With Catalent to Support Gene-Editing Medicine Pipeline
Editas Medicine, Inc. and Catalent recently announced they have entered into a strategic partnership whereby Catalent will provide support for the development, manufacturing, and clinical supply of….
PMI BioPharma Solutions Rebrands to August Bioservices, Closes Investment From Oak HC/FT to Accelerate Growth
PMI BioPharma Solutions recently announced new funding from Oak HC/FT to expand its capabilities to become a specialized, one-stop-shop CDMO for clinical and commercial injectable therapies…..
Welcome to Frontage Laboratories 2020 Podcast Series. Listen to our full suite of podcasts of engaging topics from our top scientific experts.